Almac-Exostar technology integration will enable IXRS 3 users to reap the benefits of going digital
Almac Clinical Technologies, a member of the Almac Group, has announced the launch of a standardised, operationally-proven integration between its Interactive Response Technology (IRT) platform - IXRS 3 and Exostar’s Identity and Access Management Platform.
The two global companies first announced a pilot partnership in December 2016 to demonstrate a proof-of-concept for eClinical application users to benefit from Exostar’s industry-leading Single Sign-On (SSO) expediency and enhanced security.
This latest technological advance will enable users of Almac Clinical Technologies’ Interactive Response Technology (IRT) to harness Exostar’s industry-leading credentialing, federation, and web-based Single Sign-On (SSO) capabilities to seamlessly and securely log in to Almac’s IXRS 3 with credentials provided to each user by any member of the Exostar Life Sciences Community – which includes Trial Sponsors, Contract Research Organisations (CROs), cloud application providers, and others. Half of the world’s 20 largest pharmaceutical companies and nearly 15,000 industry organisations actively participate in the Exostar Life Sciences Community.
In addition, the collaboration with Exostar allows Almac to further its mission of enhancing the patient experience. The upgraded identity management capabilities within IXRS 3 created as a result of the integration eliminate a major burden on trial sites, and enable them to focus more time and energy on patient care.
Valarie Higgins, President and Managing Director of Almac Clinical Technologies, said: “I’m delighted to further expand the capabilities of the IXRS 3 solution and help broaden the ecosystem created by Exostar's identity management platform and Transcelerate's Shared investigator platform. These enhancements help to further our mission of creating a better IRT experience by reducing the burden on investigators and their teams, and leaving them with more time to spend with their patients.”
Kenny Kong, Director of Life Sciences & Health IT for Exostar added: “The clinical trials experience is going digital with the eClinical revolution, making ease of secure access a top priority. Sites need on-demand access to sponsor applications without the burden and vulnerability of juggling unique logins and credentials for each sponsor. Sponsors must quickly activate their sites and empower them with the tools they need to advance their studies. All parties require an identity and access management experience that’s simple, straightforward, and secure. The Almac/Exostar integration enables IXRS 3 users to realize those benefits.”
To learn more about this collaboration and how it can support your clinical trial, Almac Clinical Technologies and Exostar will be co-presenting at the SCOPE Summit for Clinical Ops Executives from 18–21 February in Orlando, Florida.